Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050)

•1st-line dacomitinib improved OS vs gefitinib in Asian patients with advanced NSCLC.•OS benefit with dacomitinib was maintained in Asian patients with dose reduction.•The AE profiles in Asian patients were consistent with the overall population.•Dacomitinib is a therapy option in Asian patients wit...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2021-04, Vol.154, p.176-185
Hauptverfasser:	Cheng, Ying, Mok, Tony S., Zhou, Xiangdong, Lu, Shun, Zhou, Qing, Zhou, Jianying, Du, Yingying, Yu, Ping, Liu, Xiaoqing, Hu, Chengping, Lu, You, Zhang, Yiping, Lee, Ki Hyeong, Nakagawa, Kazuhiko, Linke, Rolf, Wong, Chew Hooi, Tang, Yiyun, Zhu, Fanfan, Wilner, Keith D., Wu, Yi-Long
Format:	Artikel
Sprache:	eng
Schlagworte:	Asian Dacomitinib Epidermal growth factor receptor Non-small cell lung cancer Tyrosine kinase inhibitor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!